BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ricciardiello F, Gang Y, Palorini R, Li Q, Giampà M, Zhao F, You L, La Ferla B, De Vitto H, Guan W, Gu J, Zhang T, Zhao Y, Chiaradonna F. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene 2020;39:4103-17. [PMID: 32235891 DOI: 10.1038/s41388-020-1260-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Mallya K, Gautam SK, Aithal A, Batra SK, Jain M. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer 2021;1876:188554. [PMID: 33945847 DOI: 10.1016/j.bbcan.2021.188554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Ricciardiello F, Bergamaschi L, De Vitto H, Gang Y, Zhang T, Palorini R, Chiaradonna F. Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor. Cells 2021;10:431. [PMID: 33670598 DOI: 10.3390/cells10020431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li LQ, Zhang LH, Yuan YB, Lu XC, Zhang Y, Liu YK, Wen J, Khader MA, Liu T, Li JZ, Zhang Y. Signature based on metabolic-related gene pairs can predict overall survival of osteosarcoma patients. Cancer Med 2021;10:4493-509. [PMID: 34047495 DOI: 10.1002/cam4.3984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cable J, Pourquié O, Wellen KE, Finley LWS, Aulehla A, Gould AP, Teleman A, Tu WB, Garrett WS, Miguel-Aliaga I, Perrimon N, Hooper LV, Walhout AJM, Wei W, Alexandrov T, Erez A, Ralser M, Rabinowitz JD, Hemalatha A, Gutiérrez-Pérez P, Chandel NS, Rutter J, Locasale JW, Landoni JC, Christofk H. Metabolic decisions in development and disease-a Keystone Symposia report. Ann N Y Acad Sci 2021. [PMID: 34414571 DOI: 10.1111/nyas.14678] [Reference Citation Analysis]
5 Wang S, Wei H, Huang Z, Wang X, Shen R, Wu Z, Lin J. Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. Acta Biochim Biophys Sin (Shanghai) 2021;53:317-24. [PMID: 33432347 DOI: 10.1093/abbs/gmaa177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fu Y, Ricciardiello F, Yang G, Qiu J, Huang H, Xiao J, Cao Z, Zhao F, Liu Y, Luo W, Chen G, You L, Chiaradonna F, Zheng L, Zhang T. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Cells 2021;10:497. [PMID: 33669111 DOI: 10.3390/cells10030497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ma J, Wu C, Hart GW. Analytical and Biochemical Perspectives of Protein O-GlcNAcylation. Chem Rev 2021;121:1513-81. [DOI: 10.1021/acs.chemrev.0c00884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
8 Heishima K, Sugito N, Soga T, Nishikawa M, Ito Y, Honda R, Kuranaga Y, Sakai H, Ito R, Nakagawa T, Ueda H, Akao Y. Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis. J Clin Invest 2021;131:e139933. [PMID: 34623325 DOI: 10.1172/JCI139933] [Reference Citation Analysis]
9 Godel M, Ortone G, Anobile DP, Pasino M, Randazzo G, Riganti C, Kopecka J. Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer. Pharmaceutics 2021;13:762. [PMID: 34065551 DOI: 10.3390/pharmaceutics13050762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Lam C, Low JY, Tran PT, Wang H. The hexosamine biosynthetic pathway and cancer: Current knowledge and future therapeutic strategies. Cancer Lett 2021;503:11-8. [PMID: 33484754 DOI: 10.1016/j.canlet.2021.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gu Z, Du Y, Zhao X, Wang C. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer. Cancer Lett 2021;521:98-108. [PMID: 34461181 DOI: 10.1016/j.canlet.2021.08.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li T, Ren T, Huang C, Li Y, Yang P, Che G, Luo L, Chen Y, Peng S, Lin Y, Zeng L. S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine. Biochem Pharmacol 2021;189:114396. [PMID: 33359364 DOI: 10.1016/j.bcp.2020.114396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Campbell S, Mesaros C, Izzo L, Affronti H, Noji M, Schaffer BE, Tsang T, Sun K, Trefely S, Kruijning S, Blenis J, Blair IA, Wellen KE. Glutamine deprivation triggers NAGK-dependent hexosamine salvage. Elife 2021;10:e62644. [PMID: 34844667 DOI: 10.7554/eLife.62644] [Reference Citation Analysis]